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Abstract
It is now well established that the glutamatergic system contributes to the pathophysiology of depression. Exposure to
stress, a major precipitating factor for depression, enhances glutamate release that can contribute to structural
abnormalities observed in the brain of depressed subjects. On the other hand, it has been demonstrated that NMDA
antagonists, like ketamine, exert an antidepressant effect at preclinical and clinical levels. On these bases, the purpose of our
study was to investigate whether chronic mild stress is associated with specific alterations of the NMDA receptor complex,
in adult rats, and to establish whether concomitant antidepressant treatment could normalize such deficits. We found that
chronic stress increases the expression of the obligatory GluN1 subunit, as well as of the accessory subunits GluN2A and
GluN2B at transcriptional and translational levels, particularly in the ventral hippocampus. Concomitant treatment with the
antidepressant duloxetine was able to normalize the increase of glutamatergic receptor subunit expression, and correct the
changes in receptor phosphorylation produced by stress exposure. Our data suggest that prolonged stress, a condition that
has etiologic relevance for depression, may enhance glutamate activity through post-synaptic mechanisms, by regulating
NMDA receptors, and that antidepressants may in part normalize such changes. Our results provide support to the notion
that antidepressants may exert their activity in the long-term also via modulation of the glutamatergic synapse.
Citation: Calabrese F, Guidotti G, Molteni R, Racagni G, Mancini M, et al. (2012) Stress-Induced Changes of Hippocampal NMDA Receptors: Modulation by
Duloxetine Treatment. PLoS ONE 7(5): e37916. doi:10.1371/journal.pone.0037916
Editor: Xin-Yun Lu, University of Texas Health Science Center at San Antonio, United States of America
Received November 21, 2011; Accepted April 30, 2012; Published May 29, 2012
Copyright:  2012 Calabrese et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This publication was made possible by grants to M. A. Riva from the Ministry of Health (Ricerca Finalizzata RF 2007 conv/42), from Regione Lombardia
(Accordo Quadro 2010). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional
external funding received for this study.
Competing Interests: The authors have read the journal’s policy and have the following conflicts: Dr. Michele Mancini is an employee of Eli Lilly Italia holding Eli
Lilly nonqualified stock option shares. Eli Lilly markets duloxetine as Cymbalta. There are no patents, products in development or other marketed products to
declare. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors.
* E-mail: M.Riva@unimi.it
Introduction
Major depression is a serious, debilitating, life-shortening illness
affecting millions of people worldwide, which arises from the
complex interaction between susceptibility genes and environ-
mental factors, such as stress [1]. Available drugs, which have been
used for more than 50 years, are based on the increase of biogenic
amines at synaptic level. While these treatments require 2–4 weeks
to produce a clinically meaningful improvement, only 60–65% of
patients respond to the initial regimen and, among these, less than
half reach remission or become symptom-free [2].
A major obstacle to the development of more effective
treatments for major depression has been the limited understand-
ing of its pathophysiology, and of the mechanisms that may be
relevant for clinical efficacy. Within this context, dysfunction of the
glutamatergic system has emerged as a major pathological feature
in depression, and may represent a target for pharmacological
intervention [3].
Genetic evidence for the involvement of the glutamatergic
pathway in emotional regulation has been obtained by analyzing
mice with genetically engineered NMDA receptor genes [4,5].
Early studies also showed that acute restraint stress induces an
increase of extracellular levels of excitatory neurotransmitters
(glutamate and aspartate) in different brain structures [6], and,
more recently, that chronic stress causes alterations of the
glutamatergic system, which may lead to dendrite retraction in
hippocampal subfields [7,8]. Moreover, animals which undergo
chronic restraint stress paradigms show an increase in basal, as
well as in depolarization-dependent, glutamate release from
hippocampal synaptosomes, suggesting a dysregulation in the
mechanism responsible for termination of glutamate secretion [9].
Based on these premises, several glutamatergic modulating
agents have been used to revert the behavioural and molecular
alterations present in mood disorders. The hypothesis that NMDA
antagonists have antidepressant properties was first proven after
the examination of several glutamatergic modulators in a murine
variant of the forced swim test [10]. At clinical level, a
subanesthetic dose of ketamine, a non-selective NMDA receptor
antagonist, has been shown to induce rapid antidepressant effects
that are sustained for several days after a single infusion [11,12].
Ketamine has also been consistently shown to possess antidepres-
sant-like properties in different rodent models of depression
[13,14,15].
Since stress-induced enhancement of glutamate release and
transmission is a crucial factor for the induction of structural and
functional changes associated with depression, and knowing that
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glutamate modulators show antidepressant activity, it would be
interesting to investigate whether currently used antidepressants
are able to interfere with stress-induced alterations of glutamate
transmission. However, this aspect has been poorly addressed.
There is, for example, evidence that antidepressant drugs can
prevent the enhancement of depolarization-dependent glutamate
release induced in the rat prefrontal/frontal cortex by acute
footshock-stress [16].
NMDA receptors are tetrameric ion channels comprising the
obligatory subunit GluN1 and the modulatory subunits NR2 (A–
D) and NR3 (A and B) [17,18]. The GluN2 subunits substantially
contribute to functional and anatomical diversities of NMDA
receptors. In particular, within in the adult brain, the NR2A and
NR2B subunits are highly expressed in the in structures that are
important for mood disorders. On these bases, understanding the
regulation of NR2 subunits in pathological conditions is important
to develop subunit-selective strategies aimed at a pharmacological
modulation of glutamate dysfunction [19].
On this basis, the specific aim of this study was to characterize
the alterations of the NMDA receptor complex in the chronic mild
stress (CMS) model of depression, and to establish the impact of
chronic antidepressant treatment on the observed changes. We
decided to investigate hippocampus and prefrontal cortex, two key
regions for mood disorders and stress-related pathologies. More-
over, with respect to the hippocampus we separately investigated
the ventral subregion, which is implicated in anxiety-related
behaviors, and dorsal part that has a preferential role in spatial
learning and memory [20,21].
Materials and Methods
Ethics Statement
All animal handling and experimental procedures were
performed in accordance with the EC (EEC Council Directive
86/609 1987), the Italian legislation on animal experimentation
(Decreto Legislativo 116/92), and the National Institutes of Health
Guide for the Care and Use of Laboratory Animals. All efforts
were made to minimize animal suffering and to reduce the
number of animals used. We obtained the ethics approval for this
study from the Italian Ministry of Public health, Department of
veterinary public health, approval ID 475.
Animals
Adult (3 months old) male Sprague-Dawley rats (Charles River,
Calco, Italy), weighing 225–250 g at the start of the experiment,
were housed in groups of 3 per cage under standard conditions
(12-h light/dark cycle, light off at 7 p.m.) and were exposed to
daily handling for 2 weeks before any procedure.
Reagents
Reagents were purchased from Sigma–Aldrich (Milan, Italy),
Bio-Rad Laboratories S.r.l. Italia (Segrate, Italy), Eurofins MWG-
Operon, (Ebersberg, Germany), Tebu-bio (Magenta, Italy), GE
Healthcare Europe GmbH (Pero, Italy).
Chronic Stress Paradigms and Antidepressant Treatment
For chronic mild stress (CMS), animals were exposed for 6
weeks to a variable sequence of mild, unpredictable stressors,
manipulation that leads to a chronic depressive-like state that
develops gradually over time. The animals were exposed once or
twice daily to different stressors including food or water
deprivation, crowding, isolation, soiled caged, 2 h immobilization,
light on overnight. Controls animals were handled every 2 days
during weighing. In order to evaluate the amount of food eaten
and water drunk, every morning both experimental groups were
weighed and refilled to avoid the possibility that animals remained
without pellet and/or water. For antidepressant treatment animals
were or were not (stress or no-stress) exposed to CMS for 21 days
and then administered once a day with duloxetine, a serotonin and
noradrenaline reuptake inhibitor (SNRI) [22] (10 mg/kg, per os,
by gavage), or vehicle (hydroxyethylcellulose, HEC, 1%, 1 ml/kg,
per os, by gavage) with continued CMS (total of 42 days).
On day 43, in the morning, rats were killed by decapitation
24 h after the last duloxetine administration. The hippocampus
(dorsal and ventral) and the prefrontal cortex were rapidly
dissected. The dorsal hippocampus corresponds to the plates 25–
33 according to the atlas of Paxinos and Watson (Paxinos and
Watson 1996), whereas the ventral hippocampus corresponds to
the plates 34–43. The prefrontal cortex (defined as Cg1, Cg3, and
IL subregions corresponding to the plates 6–10 according to the
atlas of Paxinos and Watson) was dissected from 2-mm-thick slices,
whereas the hippocampus was dissected from the whole brain.
The brain specimens were frozen on dry ice and stored at 280uC
for further analysis.
RNA Preparation and Gene Expression Analysis by
Quantitative Real-time PCR
Total RNA was isolated by single step of guanidinium
isothiocyanate/phenol extraction using PureZol RNA isolation
reagent (Bio-Rad Laboratories s.r.l. Italia) according with the
manufacturer’s instructions and quantified by spectrophotometric
analysis. Following total RNA extraction, the samples were
processed for real-time polymerase chain reaction (RT-PCR) to
assess GluN1, Glun2A and GluN2B mRNA levels. An aliquot of
each sample was treated with DNase to avoid DNA contamina-
tion. RNA was analyzed by TaqMan qRT-PCR instrument
(CFX384 real time system, Bio-Rad Laboratories, Italy) using the
iScriptTM one-step RT-PCR kit for probes (Bio-Rad Laborato-
ries). Samples were run in 384 well formats in triplicate as
multiplexed reactions with a normalizing internal control (36B4).
Primer sequences used (Table 1) were purchased from Eurofins
MWG-Operon.
Thermal cycling was initiated with an incubation at 50uC for
10 min (RNA retrotranscription) and then at 95uC for 5 min
(TaqMan polymerase activation). After this initial step, 39 cycles of
PCR were performed. Each PCR cycle consisted of heating the
samples at 95uC for 10 s to enable the melting process and then
for 30 s at 60uC for the annealing and extension reactions. A
comparative cycle threshold (Ct) method was used to calculate the
relative target gene expression.
Analysis of NMDA Subunit Protein Levels
Western blot analysis was used to investigate NMDA subunit
protein levels in the crude synaptosomal fraction. Tissues were
Table 1. Sequences of forward and reverse primers used in
real time PCR analysis.
FORWARD primer REVERSE primer
GluN1 TCATCTCTAGCCAGGTCTACG CAGAGTAGATGGACATTCGGG
GluN2A GCACCAGTACATGACCAGATTC ACCAGTTTACAGCCTTCATCC
GluN2B TTCATGGGTGTCTGTTCTGG GGATGTTGGAGTGGGTGTTG
36B4 TTCCCACTGGCTGAAAAGGT CGCAGCCGCAAATGC
doi:10.1371/journal.pone.0037916.t001
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manually homogenized using a glass-glass potter in a pH 7.4 cold
buffer containing 0.32 M sucrose, 0.1 mM EGTA, 1 mM HEPES
solution in presence of a complete set of protease (Roche) and
phosphatase (Sigma-Aldrich) inhibitors. The total homogenate was
centrifuged at 2,500 rpm for 10 min at 4uC. The supernatant
obtained was centrifuged at 10,000 g for 15 min at 4uC to obtain a
pellet corresponding to the crude synaptosomal fraction which was
re-suspended in a buffer (20 mM HEPES, 0.1 mM dithiothreitol
(DTT), 0.1 mM EGTA) with protease and phosphatase inhibitors.
Total protein content was measured according to the Bradford
Protein Assay procedure (Bio-Rad Laboratories), using bovine
serum albumin as calibration standard.
Equal amounts of protein were run under reducing conditions
on 10% SDS-polyacrylamide gels and then electrophoretically
transferred onto nitrocellulose membranes (Bio-Rad Laboratories).
The blots were blocked with 10% nonfat dry milk and then
incubated with the primary antibodies summarized in the Table 2.
Membranes were then incubated for 1 h at room temperature
with the opportune secondary antibody (see Table 2), and
immunocomplexes were visualized by chemiluminescence using
the ECL Western Blotting kit (GE Healthcare Europe GmbH).
Results were standardized using b-actin as the control protein,
which was detected by evaluating the band density at 43 kDa.
Protein levels were calculated by measuring the optical density of
the autoradiographic bands using Quantity One software (Bio-
Rad Laboratories). To ensure that autoradiographic bands were in
the linear range of intensity, different exposure times were used.
Statistical Analyses
The effects of stress and/or antidepressant treatment were
analyzed with a two-way analysis of variance (ANOVA) followed
by Single Contrast Post Hoc Test (SCPHT). Significance for all
tests was assumed for p,0.05. Data are presented as means 6
standard error (SEM). For graphic clarity, results are presented as
mean percent of No Stress/Vehicle-treated rats.
Results
Modulation of Glutamate NMDA Receptor Subunit
Expression in CMS Rats
The purpose of this study was dual. On one hand we want to
investigate the effect of chronic mild stress on different component
of the glutamatergic system, on the other we examined the impact
of chronic antidepressant treatment on the changes produced by
prolonged stress exposure. To this purpose, the SNRI duloxetine
was given for 3 weeks to either sham or CMS rats, starting from
the end of the third week of stress.
As shown in Fig. 1A, in ventral hippocampus we found a
significant effect of stress (F1,47 = 16.186, p,0.001) on GluN1
expression as well as a significant stress X drug interaction
(F1,47 = 12.790, p,0.001): indeed, the mRNA levels for the key
NMDA receptor subunit were significantly increased following
CMS in vehicle-treated rats (+125625%, p,0.001 vs. No Stress
animals), an effect that was significantly reduced in rats chronically
administered with duloxetine (23868%, p,0.001 vs. Stress
animals). A similar pattern of changes was also found with respect
to GluN2B, with a statistically significant stress X drug interaction
(F1,46 = 23.332, p,0.001). In fact, duloxetine treatment, which did
not alter GluN2B mRNA levels in sham animals, was able to
normalize (25167%, p,0.001 vs Stress animals) the increased
expression found in CMS rats (+14167%, p,0.001 vs No Stress
animals) (Fig. 1C).
Conversely, the regulation of GluN2A did not undergo similar
changes. In fact, the significant stress X drug interaction
(F1,45 = 4.260, p,0.05) was due to the fact that the antidepressant
increased the mRNA levels of GluN2A in sham animals
(+62615%, p,0.001 vs No Stress animals), but it was not able
to counteract the enhanced mRNA levels for this subunit
(+52613%, p,0.001 vs Stress animals) when given to CMS rats
(Fig. 1B).
In dorsal hippocampus (Fig.1D–F) we found only a significant
effect of the chronic stress only regard to the gene expression of
GluN2B (Fig. 1F) (F1,42 = 13.325, p,0.001). In fact, CMS
increased the levels of this specific subunit (+4166% p,0.01 vs.
No Stress animals), while duloxetine did not exert any effects.
On the contrary, in prefrontal cortex (Fig. 1G–I), we observed
only a significant stress X drug interaction (F1,43 = 4.995, p,0.05).
Specifically chronic stress significantly increased GluN1 mRNA
levels (+44616% p,0.01 vs. No Stress animals), effects corrected
by the duloxetine treatment (23067%, p,0.05 vs Stress animals).
Modulation of Glutamate NMDA Receptor Subunit
Protein Levels and Phosphorylation in CMS Rats
We next decided to examine the protein levels of NMDA
receptor subunits, specifically in the crude synaptosomal fraction.
The analysis was carried out on total protein levels as well as on
their phosphorylated forms, a measure that may hold implications
with regard to sub-cellular trafficking, activation and synaptic
localization [17,18]. Figure 2 displays prototypical western blot
analyses of these proteins. (Fig.2).
When investigating the levels of GluN1, we found that the
changes in the total receptor subunit protein did not reflect the
alterations found at mRNA levels, since CMS did not alter its
expression, whereas chronic duloxetine led to a significant increase
Table 2. Conditions of the antibodies used in the Western blot analysis.
Primary antibody Secondary antibody
Phospho GluN1 (Ser 896) 1:1000 (Santa Cruz), 4uC, O/N anti-rabbit, 1:5000, RT, 1 h
Phospho GluN1 (Ser 897) 1:2500 (Cell Signaling), 4uC, O/N anti-rabbit, 1:5000, RT, 1 h
Phospho GluN2B (Ser 1303) 1:1000 (Upstate), 4uC, O/N anti-rabbit, 1:2000, RT, 1 h
Phospho GluN2B (Tyr 1472) 1:1000 (Millipore), 4uC, O/N anti-rabbit, 1:2000, RT, 1 h
Total GluN1 1:1000 (Zymed), 4uC, O/N anti-mouse, 1:3000, RT, 1 h
Total GluN2A 1:1000 (Zymed), 4uC, O/N anti-mouse, 1:2000, RT, 1 h
Total GluN2B 1:1000 (Santa Cruz), 4uC, O/N anti-goat, 1:2000, RT, 1 h
b-actin 1:10000 (Sigma), 4uC, O/N anti-mouse, 1:10000, RT, 1 h
doi:10.1371/journal.pone.0037916.t002
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of GluN1 protein levels in the synaptosomal fraction of sham
(+39611%, p,0.05 vs. No Stress animals) but not of CMS
exposed rats (2964%, p.0.05 vs. No Stress animals). The levels
of GluN2A (Fig. 3B) mirrored only in part the changes found in
gene expression, since, similarly to the modulation of its mRNA
levels, CMS produced a significant up-regulation of its protein
levels in the synaptosomal fraction (+3964%, p,0.05). Chronic
duloxetine completely reversed the up-regulation found in stressed
rats, and it produced a slight, although not significant, elevation of
receptor subunit expression in control animals (+3168%,
p.0.05). With respect to GluN2B (Fig. 3C), we found that, in
line with mRNA changes, CMS increased its total protein levels in
the synaptosomal compartment, although duloxetine failed to
normalize such effect.
Interestingly, when looking at phospho/total GluN1 levels, the
pattern was quite similar to the modifications found at mRNA
Figure 1. Modulation of NMDA receptor subunits expression by chronic stress and antidepressant treatment in rat brain. The mRNA
levels of GluN1 (A, D, G), GluN2A (B, E, H) and GuN2B (C, F, I) were measured in ventral hippocampus (A, B, C), dorsal hippocampus (D, E, F) and
prefrontal cortex (G, H, I) of non stressed and chronically stressed rats, treated for 21 days with vehicle or duloxetine and killed 24 hours after the last
stress. The data, expressed as a percentage of No Stress/Vehicle (set at 100%), are the mean 6 SEM of at least 10–12 independent determinations.
*p,0.05, **p,0.01, ***p,0.01 vs. No Stress/Vehicle; $p,0.05, $$$p,0.001 vs. Stress/Vehicle (two-way ANOVA with SCPHT).
doi:10.1371/journal.pone.0037916.g001
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levels (Fig. 4A,B). In particular, for the two phosphorylated sites
(pSer896 and pSer897) the ratio phospho/total GluN1 was
significantly increased upon exposure to CMS (+5166%,
p,0.01 and +39613%, p,0.05, respectively), an effect that was
normalized when duloxetine was given during the last three weeks
of stress exposure. Exposure to the antidepressant tended to reduce
the phospho/total ratio also in sham animals (230613% and
23065% respectively for serine 896 and for serine 897), although
the effect did not reach statistical significance.
Furthermore, neither CMS nor the pharmacological treatment
was able to alter the degree of GluN2B phosphorylation at two
different sites: pSer1303, which is driven by aCaMKII [23], and
pTyr1472, that linked to the activation of the fyn pathway [24]
(Fig. 4C,D).
Discussion
The data emerging from the present work provide novel
information with respect to changes of glutamate NMDA receptor
subunits as a consequence of exposure to CMS, which are to great
extent normalized by concomitant treatment with the antidepres-
sant duloxetine. While some of the changes found in the
synaptosomal compartment may be sustained by transcriptional
mechanisms, there is also evidence that some critical modifications
may occur through post-translational modifications, including
changes in the phosphorylation of specific receptor subunits, which
is well-recognized as being a key process involved in receptor
trafficking and synaptic localization [18].
While changes in the mRNA levels of the glutamate NMDA
receptor subunits may occur in different brain structures, the
major effect take place in the ventral hippocampus, which is
strongly relates to stress, emotion, and mood [20].
Although the involvement of glutamate in major depression
dates back to several years ago [25], there has been renewed
interest in this system because of the observation that NMDA
receptor antagonists, such as ketamine, may exert rapid (within
2 hours) antidepressant effects [3,12]. In particular, pioneer work
from Zarate and coworkers has demonstrated that a single
intravenous administration of ketamine at a sub-anesthetic dose
Figure 2. Representative Western blotting of NMDA receptor
subunits in ventral hippocampus. Representative western blot
analysis of of GluN1, GluN2A, GluN2B, phospho GluN1 (Ser896),
phospho GluN1 (ser897), phospho GluN2B (Ser1303), phospho GluN2B
(Tyr1472) expression in crude synaptosomal fraction from adult brain
ventral hippocampus. b-actin is shown as control for comparison. Veh
vehicle, dlx duloxetine, CMS chronic mild stress, CMS + dlx chronic mild
stress + duloxetine. Experimental conditions are described in Material
and Methods.
doi:10.1371/journal.pone.0037916.g002
Figure 3. Modulation of protein levels for NMDA receptor subunits by CMS and antidepressant treatment in rat ventral
hippocampus. The protein levels of GluN1 (A), GluN2A (B) and GuN2B (C) were measured in the crude synaptosomal fraction of ventral
hippocampus of non stressed and chronically stressed rats, treated for 21 days with vehicle or duloxetine and killed 24 hours after the last stress. The
data, expressed as a percentage of No Stress/Vehicle (set at 100%), are the mean 6 SEM of at least 5–7 independent determinations. *p,0.05 vs. No
Stress/Vehicle; $p,0.05, $$p,0.01 vs. Stress/Vehicle (two-way ANOVA with SCPHT).
doi:10.1371/journal.pone.0037916.g003
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elicited a rapid improvement of depressive symptoms in resistant
patients [12]. It may be inferred that depression-related dysfunc-
tions could be associated with a state of excessive function of the
glutamatergic system and/or activation of glutamate receptors,
which can be reversed by NMDA receptor blockade [3,26]. Such
view is in accordance with the possibility that excessive NMDA
receptor activation represents the point of convergence of different
elements that participate to depression susceptibility. One of the
main vulnerability factors is stress, which may enhance glutamate
release, eventually leading to toxic effects on selected neuronal
populations [16,27]. Our results provide support to this possibility
and suggest a novel mechanism that may contribute to the adverse
effects of prolonged stress exposure, namely an up-regulation of
the NMDA receptor complex occurring at transcriptional level as
well as through post-translational mechanisms (receptor phos-
phorylation at key amino acids) that govern receptor localization
and function. This ‘up-regulation’ may eventually amplify
glutamatergic signalling, leading to an imbalance of neurotrans-
mitter function, particularly in the ventral hippocampus.
We have previously shown that the phosphorylation of GluN1
on Ser 896 is not affected by acute stress [28], suggesting that the
changes observed after CMS may represent a neuroadaptive
consequence rather than a rapid modification of receptor
activation due to stress exposure. It may be inferred that the
glutamatergic system undergoes different changes based on timing
and length of the adverse experience. Acute stress can increase the
release of glutamate in different brain regions, with a main effect in
the prefrontal cortex [6,16]. This may initiate downstream
changes, which could result in coping or susceptibility on the
basis of the intracellular pathways that are activated. For example,
acute glucocorticoids modulate synaptic transmission and plasticity
through AMPA receptors, promoting the consolidation of
behavior [29]. On the other hand, chronic stress may lead to a
prolonged increase of glutamate levels [30] that, as suggested by
the present results, may synergize with a dysfunctional receptor at
post-synaptic level.
The transcriptional changes of GluN1 and GluN2B subunits
induced by CMS are normalized by chronic exposure to the
antidepressant duloxetine, whereas the modulation of GluN2A
appears to be somewhat different. Indeed, the significant up-
regulation observed in stressed animals is not normalized by
antidepressant treatment, whereas chronic duloxetine was able to
increase its mRNA levels in control rats.
Previous work has shown that the NMDA receptor complex
undergoes changes following chronic treatment with antidepres-
sants in normal animals, which lead to a reduction of its function
[10,31,32]. Our results show that administration of duloxetine in
control animals has limited effect on the expression (mRNA and
protein) of NMDA receptor subunits.
One interesting, and previously unexplored, mechanism, is the
modulation of the phosphorylation state of the GluN subunits in
the synaptosomal compartment. Our results demonstrate that the
Figure 4. Modulation of GluN1 and GluN2B subunits phosphorylation by CMS and antidepressant treatment in rats ventral
hippocampus. The levels of pGluN1Ser896 and pGluN1Ser897 (A,B) or pGluN2BSer1303 and pGluN2BTyr1472 (C,D) were measured in the crude
synaptosomal fraction of ventral hippocampus of non stressed and chronically stressed rats, treated for 21 days with vehicle or duloxetine and killed
24 hours after the last stress. The data represent the ration between phosphorylated and total subunit levels. Results, expressed as a percentage of
No Stress/Vehicle (set at 100%), are the mean 6 SEM of at least 5–7 independent determinations. *p,0.05, **p,0.01 vs. No Stress/Vehicle; $p,0.05
vs. Stress/Vehicle (two-way ANOVA with SCPHT).
doi:10.1371/journal.pone.0037916.g004
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phosphorylation of GluN1 on serine 896 and 897 is enhanced by
stress, which may lead to an increased synaptic localization of the
receptor. Indeed, the phosphorylation of GluN1 promotes the exit
of the subunit from the endoplasmatic reticulum and increases
surface membrane localization [18].
Chronic treatment with the antidepressant duloxetine produced
a non significant reduction of GluN1 and GluN2B phosphoryla-
tion in normal animals, suggesting that prolonged exposure to
antidepressants may indeed lead to a functional inhibition of the
receptor complex [18,31,32,33]. More importantly, chronic
duloxetine administration led to a significant decrease of GluN1
phosphorylation in stressed rats, with a normalization of the
changes observed after exposure to CMS. These results, together
with the evidence that mice expressing mutant GluN2A with a
Tyr-1325-Phe mutation that prevents its phosphorylation show
antidepressant-like behaviour [34], provide support to the notion
that NMDA receptor phosphorylation and downstream signalling
can modulate depression-related behaviour.
Based on these data, it may be hypothesized that one important
adaptive change occurring after long term exposure to duloxetine
is a modulation of the GluN subunits transcription and of their
localization and activation at synaptic level, which may correct
abnormalities produced by a prolonged stress exposure. Interest-
ingly, it has been recently demonstrated that a single dose of
ketamine completely reverses the behavioral deficits caused by
long-term exposure to CMS, with similar effects occurring also
with a selective GluN2B antagonist, Ro 25-6981 [14,35,36]. These
data suggest that the ‘normalization’ of glutamate-related
dysfunctions may indeed represent an important component of
the therapeutic response, which may ultimately lead to an
improvement of the structural alterations associated with mood
dysfunction [3].
It is feasible to hypothesize that, although the effects of classical
antidepressants and of ketamine (or glutamate NMDA receptor
antagonists) may converge on the same target, the modulation
following prolonged exposure to antidepressants is probably part
of a complex array of neuroadaptive changes produced by
pharmacological intervention [37,38].
Differently from duloxetine, we have previously shown that sub-
chronic electroconvulsive treatment treatment produces a marked
increase of the phosphorylation of GluN2B (Ser1303), with no
effects in the obligatory subunit GluN1 [39]. Increased phosphor-
ylation of GluN2B on Ser1303 may reduce NMDA receptor
activity, presumably uncoupling this receptor subunit from its
signalling partner CaMKII [40]. This suggests that antidepressant
treatments may differentially regulate the expression and function
of NMDA receptor subunits, a common endpoint being the
reduction of its functional activity.
Antidepressant activity may therefore originate directly from the
reduced function of NMDA receptors, as indicated by our data as
well as by previous work that investigated receptor binding and
function [15], but it may also be related to increased function of
AMPA receptors. Indeed, antidepressant-like effects produced by
ketamine treatment and by the GluN2B selective antagonist Ro25-
6981 are attenuated by AMPA receptor antagonism. Furthermore,
chronic ECT or chronic imipramine treatment lead to enhanced
phosphorylation or synaptic localization of GluA1 subunit [39,41].
Taken together, our results and previous published work suggest
that an important mechanism that may contribute to antidepres-
sant activity is the interference with glutamatergic neurotransmis-
sion, in order to ‘restore’ altered function in depressive-related
conditions. This may indeed occur at several levels that take into
account the complex function of this neurotransmitter. Indeed,
antidepressants may act at a pre-synaptic level, dampening the
excessive release of glutamate [16], and could also interfere with
post-synaptic mechanisms, that will globally lead to a reduction of
NMDA receptor function and transmission, eventually favoring
AMPA receptor transmission [10,31,32,39,41]. Moreover, antide-
pressants may also act on glial cells to restore their function, which
is crucial for controlling the proper concentration of glutamate at
synaptic level [14,42].
The characterization of these events and of the mechanisms that
lie downstream from the glutamatergic synapse will be important
to develop novel pharmacological strategies that, alone or in
combination with currently used drugs, may improve treatment
outcome in depressed patients.
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